Baloxavir marboxil

Baloxavir marboxil
Clinical data
Trade names	Xofluza
Other names	BXM (S-033188), BXA (S-033447)
AHFS/Drugs.com	Monograph
MedlinePlus	a618062
License data	US DailyMed: Baloxavir marboxil;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	J05AX25 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name ({(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f] [1,2,4]triazin-7-yl}oxy)methyl methyl carbonate;
CAS Number	1985606-14-1;
PubChem CID	124081896;
DrugBank	DB13997;
ChemSpider	59718643;
UNII	505CXM6OHG;
KEGG	D11021;
CompTox Dashboard (EPA)	DTXSID601027758 ;
Chemical and physical data
Formula	C27H23F2N3O7S
Molar mass	571.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCOC(C(C=C1)=O)=C(N1N([C@@H]2C3=CC=CC=C3SCC4=C(F)C(F)=CC=C24)[C@@]5([H])N6CCOC5)C6=O)OC;
	InChI InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1; Key:RZVPBGBYGMDSBG-GGAORHGYSA-N;

Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication used for the treatment of influenza A and influenza B. It was approved for medical use both in Japan and in the United States in 2018, and is taken by mouth. It can reduce the duration of flu symptoms by about 1-2 days in some people, but can also develop selection of resistant mutants that render it ineffectual; however studies noted this was seen mostly in children that were studied.

Baloxavir marboxil was developed as a prodrug strategy, with its metabolism releasing the active agent, baloxavir acid. Baloxavir acid then functions as enzyme inhibitor, targeting the influenza virus' cap-dependent endonuclease activity, used in "cap snatching" by the virus' polymerase complex, a process essential to its life-cycle.

The most common side effects of baloxavir marboxil include diarrhea, bronchitis, nausea, sinusitis, and headache.

The US Food and Drug Administration considers baloxavir marboxil to be a first-in-class medication.